Get more information on eClinical Solutions Market - Request Free Sample Report
The eClinical Solutions Market Size was valued at USD 10.10 billion in 2023 and is expected to reach USD 32.84 billion by 2032 and grow at a CAGR of 14.01% over the forecast period 2024-2032.
To help speed up the clinical design process, eClinical solutions manage clinical experience and techniques. An eClinical arrangement is a mechanized arrangement (programming or potentially equipment) that upholds clinical testing tasks via computerizing beforehand manual tasks. With an expansion in clinical preliminaries in the drug and biotechnology businesses, the requirement for eClinical arrangements is expanding.
There is indeed a significant trend of exporting eClinical solutions due to the large patient pool and inexpensive operational costs in emerging nations such as Korea, Taiwan, and India. A clinical trial management system commonly sends data to a business intelligence system, which acts as a digital dashboard for trial managers. As they can collect and organise data that may be shared with multiple care providers and disseminated across multiple systems, clinical trial management systems are both cost and time effective. Electronic health records, electronic permission forms, integrating technologies, electronic data capture, and clinical data management systems are all part of eClinical solutions. By assuring effective management of the lengthy clinical research procedure, e-clinical solutions aid researchers in the end-to-end clinical research process. Because of technical improvements and government incentives, the market for eClinical solutions is increasing. It helps clinical research companies with team collaboration, regulatory document management, supply chain management, site performance monitoring, and reporting, all of which are expected to drive demand for eClinical solutions during the forecast period.
DRIVERS
Biopharmaceutical and pharmaceutical companies are increasing their R&D spending.
Clinical research studies are becoming more expensive to conduct due to rising operational costs and regulatory restrictions.
Clinical Trials Expenditure Is Increasing
Chronic Diseases Are Getting Worse
Smart Devices are being used more frequently in healthcare administration.
RESTRAINTS
Clinical Trials are in short supply due to a scarcity of healthcare professionals and patients.
Data security and privacy
eClinical systems are known for their high implementation costs.
OPPORTUNITIES
Clinical research activities in rising Asian countries are becoming more active.
Increasing Precision Medicine Research and Development
The rise of precision medicine is expected to revolutionise the global market for eclinical solutions.
CHALLENGES
Concerns about patient privacy
IMPACT OF COVID-19
The COVID-19 pandemic has prompted the healthcare and life sciences industries to think creatively about how to advance the best, most competent solutions, methods, and processes to assist clinical researchers in introducing safe and effective treatments to the public faster. As a result, many life sciences organisations are attempting to capitalise on this momentum and alter their processes. The desire to use all available resources, technologies, and digital capabilities to complete clinical trials more quickly and effectively is propelling the eclinical solution software industry forward. The push for decentralised trials, with protocol designs, technology, and methods that provide more significant remote input in research, is a critical initiative for the pandemic.
Clinical studies are being stalled and postponed in order to finish the coronavirus pandemic, which is putting heart disease, cancer, and diabetes research on the back burner. Many companies have communicated clinical trial disruptions due to the outbreak since March of this year. By emphasising compliance, safety, and a risk-based strategy, data services are expected to improve eclinical solutions revenue. As a result of the COVID-19 epidemic, trial participation has decreased dramatically.
By Product:
Clinical Analytics Platform
Clinical Trial Management Systems (CTMS)
Clinical Data Integration Platform
Electronic Clinical Outcome Assessment (eCOA)
Safety Solutions
Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)
Randomization and Trial Supply Management (RTMS)
By Mode of Delivery:
Licensed Enterprise (On-premise)
Web-hosted (On-demand)
Cloud-based (SaaS)
By Clinical Trial Phase:
Phase I
Phase II
Phase III
Phase IV
By End User:
Pharmaceutical and Biopharmaceutical Companies
Consulting Service Companies
Medical Device Manufacturers
Contract Research Organizations
Academic Research Institutions
Hospitals
By Product
Due to the increasing importance of high-quality clinical data, eCOA is expected to be the fastest-growing market during the projection period. eCOA aids in the preservation of overall quality and is becoming more widely used in the measurement of patient-, clinician-, and observer-reported outcomes. The data gathering process on eCOA platforms improves the quality of data collected, improves data collection methods, and allows for better data analysis.
By Mode of Delivery
The segment's prominence can be due to associated benefits such ease of access, usability, and cheaper investment requirements. Because web-hosted goods are highly configurable, providers can tailor information display for different user groups. These products also have a higher level of compatibility. All through the forecast period, the category is expected to hold its position.
Due to integrated features like flexibility, high accessibility, low handling costs, and quick data backup, the cloud-based category is expected to grow at an exponential CAGR of 13.5 percent over the projection period. These systems deliver real-time data, allowing users to make quick decisions and give high-quality information for risk-based monitoring. The need for cloud-based systems is expected to increase as a result of these benefits.
By Clinical Trial Phase
The segment's rise is being fueled by the increasing need for clinical data management software to reduce overall costs and increase process efficiency. The segment's growth is being aided by an increasing number of medications successfully advancing to phase III. The efficacy of a medicine is studied in Phase III with a group of more than 1,000 patients. Even as patients in a study grows, so does the difficulty of the study, which drives demand for computer-based data management systems and accelerates adoption of eClinical solutions.
Due to the great importance of these systems in predicting future outcomes and eliminating medication candidates with the lowest potential of success, the phase I segment is expected to be the most promising section over the forecast period. The discovery of novel medications is booming thanks to advances in biological modelling systems and customized medicine technology. The segment's growth is likely to be fueled by a huge number of phase I trials and the complicated management and analysis of data collected during diverse investigations.
By End User
In 2021, the CROs category dominated the market for eClinical solutions, with a revenue share of more than 37%. The segment is expected to develop at a significant CAGR during the forecast period, owing to pharmaceutical companies' growing desire to cut overall spending. The growing use of eClinical solutions in research is expanding the segment's potential. The expanded development of this fragment may be ascribed to the upsides of re-appropriating clinical preliminaries to CROs. Cost reserve funds, expanded help effectiveness, expanded efficiency, and a more noteworthy spotlight on key improvement regions essential to an organization's prosperity are only a couple of the up-sides. Over the projection period, the pharma and biotech companies’ industry is expected to grow significantly. This is due to researchers' growing use of eClinical technologies, which improve clinical trials and reduce research workload. Biotechnology and pharmaceutical organisations can use technologies like this to identify clinical trial procedure bottlenecks. As a result, researchers in pharmaceutical and biotechnology organisations are increasingly looking for eClinical solution for clinical research programmes.
In 2020, North America held the highest proportion of the global eClinical solutions market. Rising government regulations to help clinical preliminaries, continuous item upgrades and new item dispatches by vital participants in the eClinical arrangement market, and an expansion in the quantity of organizations for novel medication improvement are driving interest for eClinical arrangements in this area.
Need any customization research on eClinical Solutions Market - Enquiry Now
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Some of the major key players are Bioclinica, CRF Health, Dassault Systemes, Datatrak International, Inc., ERT Clinical, eClinicalWorks, Oracle, Parexel International Corporation, and other players.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 10.10 Billion |
| Market Size by 2032 | USD 32.84 Billion |
| CAGR | CAGR of 14.01% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Clinical Analytics Platform, CTMS, Clinical Data Integration Platform, eTMF, eCOA, Safety Solutions, EDC and CDMS, RTMS, Others) • By Mode of Delivery (Licensed Enterprise (On-premise), Web-hosted (On-demand), Cloud-based (SaaS)) • By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV) • By End User (Pharmaceutical and Biopharmaceutical Companies, Consulting Service Companies, Medical Device Manufacturers, Contract Research Organizations, Academic Research Institutions, Hospitals) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bioclinica, CRF Health, Dassault Systemes, Datatrak International, Inc., ERT Clinical, eClinicalWorks, Oracle, Parexel International Corporation, and other players. |
| Drivers | • Biopharmaceutical and pharmaceutical companies are increasing their R&D spending. • Clinical research studies are becoming more expensive to conduct due to rising operational costs and regulatory restrictions. • Clinical Trials Expenditure Is Increasing |
| Restraints | • Clinical Trials are in short supply due to a scarcity of healthcare professionals and patients. • Data security and privacy • eClinical systems are known for their high implementation costs. |
Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, Fundamental Research.
Licensed Enterprise (On-premise), Web-hosted (On-demand), Cloud-based (SaaS) are the sub segments of by Mode of Delivery.
Key drivers of the eClinical Solutions Market the demand for low-cost drug discovery and development is growing, and Supporting Regenerative Medicine Research with Public and Private Funding.
Segments of eClinical Solutions market are By Product, By Mode of Delivery, By Clinical Trial Phase, and By End User.
eClinical Solutions Market Size was valued at USD 10.10 billion in 2023, and expected to reach USD 32.84 billion by 2032, and grow at a CAGR of 14.01% over the forecast period 2024–2032.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. eClinical Solutions Market Segmentation, By Product
8.1 Clinical Analytics Platform
8.2 Clinical Trial Management Systems (CTMS)
8.3 Clinical Data Integration Platform
8.4 Electronic Trail Master Files (eTMF)
8.5 Electronic Clinical Outcome Assessment (eCOA)
8.6 Safety Solutions
8.7 Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)
8.8 Randomization and Trial Supply Management (RTMS)
8.9 Others
9. eClinical Solutions Market Segmentation, By Mode of Delivery
9.1 Licensed Enterprise (On-premise)
9.2 Web-hosted (On-demand)
9.3 Cloud-based (SaaS)
10. eClinical Solutions Market Segmentation, By Clinical Trial Phase
10.1 Phase I
10.2 Phase II
10.3 Phase III
10.4 Phase IV
11. eClinical Solutions Market Segmentation, By End User
11.1 Pharmaceutical and Biopharmaceutical Companies
11.2 Consulting Service Companies
11.3 Medical Device Manufacturers
11.4 Contract Research Organizations
11.5 Academic Research Institutions
11.6 Hospitals
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 USA
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4 Asia-Pacific
12.4.1 Japan
12.4.2 South Korea
12.4.3 China
12.4.4 India
12.4.5 Australia
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.1 Israel
12.5.2 UAE
12.5.3 South Africa
12.5.4 Rest
12.6 Latin America
12.6.1 Brazil
12.6.2 Argentina
12.6.3 Rest of Latin America
13. Company Profiles
13.1 Bioclinica
13.1.1 Financial
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 CRF Health
13.3 Dassault Systemes
134 Datatrak International, Inc.
13.5 ERT Clinical
13.6 eClinicalWorks
13.7 Oracle
13.8 Parexel International Corporation
14 Competitive Landscape
14.1 Competitive Benchmark
14.2 Market Share Analysis
14.3 Recent Developments
15 Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Pharmaceutical Excipients Market Size was valued at USD 9.09 billion in 2023 and is expected to reach USD 14.52 billion by 2031, and grow at a CAGR of 6.02% over the forecast period 2024-2031.
The Skin Cancer Treatment Market Size was valued at USD 10.98 Billion in 2023 and is expected to reach USD 20.74 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Computerized Physician Order Entry Market Size was valued at USD 1.81 billion in 2023, and expected to reach USD 3.25 billion by 2032, and grow at a CAGR of 6.7% over the forecast period 2024-2032.
The Teleradiology Market Size was valued at USD 2.70 billion in 2023 and is expected to reach USD 7.17 billion by 2031 and grow at a CAGR of 8.4% over the forecast period 2024-2031.
The Companion Diagnostics Market Size, valued at USD 7.66 billion in 2023, is expected to reach USD 21.15 billion by 2032, with a CAGR of 11.9%.
The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is expected to reach USD 50.2 Billion by 2032, at 4.00% CAGR by 2024-2032
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
